

Cytotoxic Styryl-Lactones from the Leaves and Twigs of *Polyalthia crassa*

Patoomratana Tuchinda,^{*,†} Bamroong Munyoo,[†] Manat Pohmakotr,[†] Pongchan Thinapong,[†] Samaisukh Sophasan,[‡] Thawatchai Santisuk,[§] and Vichai Reutrakul[†]

Department of Chemistry and Department of Physiology, Faculty of Science, Mahidol University, Rama VI Road, Bangkok 10400, Thailand, and The Forest Herbarium, Royal Forest Department, Bangkok 10900, Thailand

Received July 6, 2006


Four new styryl-lactones, crassalactones A–D (**1–4**), were isolated from a cytotoxic ethyl acetate-soluble extract of the leaves and twigs of *Polyalthia crassa*, together with seven known compounds, (+)-3-acetylalthalactone, (+)-althalactone, aristolactam AII, cinnamic acid, (+)-goniofufurone, (+)-gonioppyrone, and (+)-howiinol A. Their structures were determined on the basis of spectroscopic methods. The absolute configuration of **1–3** was established by chemical conversions. Single-crystal X-ray analysis and the Mosher ester method were used to confirm the absolute stereochemistry of **4**. Cytotoxic evaluation against several mammalian cancer cell lines was performed on all new isolates, aristolactam AII, and the modified (+)-tricinamate derivative **11** obtained from **1**.

Several members of the genus *Polyalthia* have been widely used in traditional medicine in Asia. In Thailand, water decoctions from the roots of *P. evecta* and *P. debilis* are used as a galactagogue^{1a,b} and for the treatment of abdominal pain,^{1a} respectively. *Polyalthia bullata* is used in Malaysia as an aphrodisiac.² From various *Polyalthia* species, many constituents showing cytotoxic,³ antimicrobial,⁴ antimalarial,⁵ and anti-HIV⁶ activities have been reported previously. Earlier chemical examinations of plants in the genus *Polyalthia* yielded diterpenes,^{3,7} triterpenes,^{6a,8} benzopyrans,⁹ 2-substituted furans,^{1b,6b,10} and various types of alkaloids.^{3d,5,11} Our previous work on *P. suberosa* has resulted in the isolation of an azaanthrazene alkaloid, kalasinamide,¹² 2-substituted furans,^{6b} and carboxamides.^{12a}

As part of our ongoing project on the discovery of new cytotoxic agents from plants, we describe herein the chromatographic separation of a cytotoxic ethyl acetate extract of the leaves and twigs of *P. crassa*, leading to the isolation of four new styryl-lactones, crassalactones A–D (**1–4**), along with the known (+)-howiinol A (**5**),¹³ (+)-goniofufurone (**6**),¹⁴ (+)-althalactone (**7**),¹⁵ (+)-3-acetylalthalactone (**8**),¹⁶ (+)-gonioppyrone (**9**),^{14a} aristolactam AII (**10**),¹⁷ and cinnamic acid. For further structural and stereochemical studies of compound **1**, (+)-tricinamate **11** was prepared from both (+)-**1** and (+)-**5**, whereas the known (+)-**6** could be converted to (+)-**2** and (+)-**3**. The modified compounds were characterized on the basis of spectroscopic methods. The four styryl-lactones **1–4**, aristolactam AII (**10**), and the semisynthetic (+)-tricinamate **11** were evaluated for their cytotoxic activities against a panel of five mammalian cancer cell lines.


Results and Discussion

(+)-Crassalactone A (**1**) displayed a molecular ion peak at m/z 380 in the EIMS, corresponding to the molecular formula $C_{22}H_{20}O_6$ and confirmed by elemental analysis. The presence of two free hydroxyls and a cinnamate group in **1** were indicated by the ion peaks at m/z 362 ($M^+ - H_2O$) and 344 ($M^+ - 2H_2O$), 148 [$(PhCH=CHCO_2H)^+$, base peak], and 131 ($PhCH=CHCO$)⁺. The IR spectrum of **1** showed an OH stretch at 3456 cm^{-1} and two C=O absorptions at 1721 and 1711 cm^{-1} . The α,β -unsaturated δ -lactone character of **1** was confirmed by the presence of a small peak at δ_C 162.3 in its ^{13}C NMR spectrum. The 1H NMR




1 R = cinnamoyl, R' = R'' = H
5 R = R' = H, R'' = cinnamoyl
11 R = R' = R'' = cinnamoyl


2 R = cinnamoyl, R' = H
3 R = H, R' = cinnamoyl
6 R = R' = H




4



7 R = H
8 R = Ac



9



10

spectroscopic data of **1** (Table 1) were closely comparable to those observed for (+)-howiinol A (**5**) obtained from the same extract (for spectroscopic data of **5**, see Supporting Information) and previously reported from *Goniothalamus howii*.¹³ The olefinic signals at δ 6.21 (d, $J = 9.7$ Hz, H-3) and 6.99 (dd, $J = 9.7$ and 5.9 Hz, H-4) were typical of an α,β -unsaturated δ -lactone, while a broad singlet at δ 2.75 (2H) confirmed the presence of two hydroxyl protons in **1**. The cinnamate group in **1** was characterized by a pair of doublets ($J = 16$ Hz each) at δ 6.32 (H-2') and 7.63 (H-3'), together with the aromatic signals at δ 7.50 (2H, H-5' and H-9') and 7.37–7.41 (3H, H-6', H-7', H-8'). By analyses of its COSY spectrum, the four oxygen-linked methine signals at δ 5.30 (dd, $J = 5.9$ and 2.7 Hz), 4.79 (dd, $J = 5.6$ and 2.7 Hz), 4.29 (t, $J = 5.6$ Hz), and 4.91 (d, $J = 5.6$ Hz) were assigned to H-5, H-6, H-7, and H-8, respectively. The ^{13}C NMR spectrum of **1** (Table 1) displayed 18 signals for 22 carbons, of which the carbon types were determined by DEPT experiments. The connectivity of the cin-

* Corresponding author. Tel: 662-2015159. Fax: 662-3547151. E-mail: septe@mahidol.ac.th.

[†] Department of Chemistry, Mahidol University.


[‡] Department of Physiology, Mahidol University.

[§] The Forest Herbarium, Royal Forest Department.


Table 1. ^1H and ^{13}C NMR Spectroscopic Data of **1–4** (in CDCl_3)

C/H	1		2		3		4	
	δ_{H} mult. (J^a)	δ_{C} mult. ^b	δ_{H} mult. (J^a)	δ_{C} mult. ^b	δ_{H} mult. (J^a)	δ_{C} mult. ^b	δ_{H} mult. (J^a)	δ_{C} mult. ^b
2		162.3 s		174.7 s		175.3 s		169.0 s
3	6.21 d (9.7)	124.6 d	2.72 dd (19.0, 5.8) 2.60 d (19.0)	35.6 t	2.67 dd (18.8, 5.6) 2.56 d (18.8)	35.8 t	6.28 d (5.6)	124.9 d
4	6.99 dd (9.7, 5.9)	140.8 d	5.02–5.05 m	77.1 d	4.99–5.03 m	77.1 d	7.29 d (5.6)	151.0 d
5	5.30 dd (5.9, 2.7)	62.8 d	5.02–5.05 m	85.3 d	4.99–5.03 m	87.0 d		114.3 s
6	4.79 dd (5.6, 2.7)	77.6 d	5.75 d (2.6)	75.5 d	4.42 br s	73.2 d	2.57 dd (14.3, 6.4) 2.31 dd (14.3, 1.9)	42.4 t
7	4.29 t (5.6)	73.4 d	4.27 dd (8.6, 2.6)	83.1 d	4.25 dd (9.2, 2.2)	82.5 d	4.42 ddd (6.4, 1.9, 1.9)	78.2 d
8	4.91 d (5.6)	73.5 d	4.68 d (8.6)	70.9 d	6.00 d (9.2)	72.9 d	5.39 d (1.9)	91.4 d
9		139.9 s		140.4 s		136.8 s		138.4 s
10	7.43 d (7.4)	126.6 d	7.31–7.46 m	126.8 d	7.48 dd (8.1, 1.5)	127.7 d	7.29–7.34 m	125.0 d
11	7.34 t (7.4)	128.7 d	7.31–7.46 m	128.6 d	7.36–7.44 m	128.7 d	7.37–7.41 m	128.7 d
12	7.28 t (7.4)	128.3 d	7.31–7.46 m	128.4 d	7.36–7.44 m	128.9 d	7.29–7.34 m	128.2 d
13	7.34 t (7.4)	128.7 d	7.31–7.46 m	128.6 d	7.36–7.44 m	128.7 d	7.37–7.41 m	128.7 d
14	7.43 d (7.4)	126.6 d	7.31–7.46 m	126.8 d	7.48 dd (8.1, 1.5)	127.7 d	7.29–7.34 m	125.0 d
1'		165.5 s		166.4 s		167.5 s		
2'	6.32 d (16.0)	116.3 d	6.55 d (16.0)	116.1 d	6.46 d (15.9)	116.7 d		
3'	7.63 d (16.0)	146.6 d	7.84 d (16.0)	147.6 d	7.76 d (15.9)	147.3 d		
4'		133.8 s		133.8 s		133.8 s		
5'	7.50 dd (7.4, 2.0)	128.2 d	7.59 dd (7.4, 2.2)	128.4 d	7.53 dd (7.5, 2.1)	128.4 d		
6'	7.37–7.41 m	128.9 d	7.31–7.46 m	129.1 d	7.36–7.44 m	129.0 d		
7'	7.37–7.41 m	130.8 d	7.31–7.46 m	131.1 d	7.36–7.44 m	131.0 d		
8'	7.37–7.41 m	128.9 d	7.31–7.46 m	129.1 d	7.36–7.44 m	129.0 d		
9'	7.50 dd (7.4, 2.0)	128.2 d	7.59 dd (7.4, 2.2)	128.4 d	7.53 dd (7.5, 2.1)	128.4 d		
OH-6					4.18 br s			
OH-7	2.75 br s						2.43 (br s)	
OH-8	2.75 br s		2.91 br s					

^a Spectra recorded at 500 MHz in CDCl_3 , using TMS as an internal reference; J values (in Hz) in parentheses. ^b Spectra recorded at 125 MHz in CDCl_3 , using CDCl_3 signal at δ_{C} 77.0 as reference; multiplicities determined by DEPT experiments.


Scheme 1. Chemical Conversions of (+)-Crassalactone A (**1**) and (+)-Howiinol A (**5**) to the (+)-Tricinamate **11**

(a) Cinnamic acid (2.2 equiv), DCC (2.3 equiv), DMAP (4 equiv), Dry CH_2Cl_2 , rt, 3 h; (b) cinnamic acid (2.2 equiv), DCC (2.3 equiv), DMAP (4 equiv), dry CH_2Cl_2 , rt, 14 h.

**Figure 1.** X-ray ORTEP diagram of (+)-howiinol A (**5**).

namate group to C-5 was indicated by the HMBC correlations of the H-5 signal to the C-2, C-3, C-4, C-6, C-7, C-1', and C-2' signals (Table S1, Supporting Information). As both (+)-**1** and (+)-**5** could be converted into the (+)-tricinamate **11** (Scheme 1) and the products obtained from both reactions (41 and 18% yields, respectively) were found to be identical (mp, optical rotation, ^1H and ^{13}C NMR data), the relative configuration of both compounds was proved to be the same. The isolated (+)-howiinol A (**5**) and the compound reported previously by Chen et al.^{13b} were confirmed by single-crystal X-ray diffraction analysis (see Figure 1). Since the absolute stereochemistry of natural (+)-howiinol A (**5**) has been proposed previously through synthesis,^{13a} the absolute configuration of (+)-crassalactone A (**1**) was determined therefore as 5*S*, 6*R*, 7*R*, and 8*R*.

The molecular formula of (+)-crassalactone B (**2**) was determined as $\text{C}_{22}\text{H}_{20}\text{O}_6$ by HRTOFMS (ESI positive) measurement for $\text{C}_{22}\text{H}_{20}\text{O}_6\text{Na}$ at m/z 403.1158 (calcd 403.1158). The weak molecular ion $[\text{M}]^+$ at m/z 380, together with the fragment ions at m/z 362 ($\text{M}^+ - \text{H}_2\text{O}$), 148 $[(\text{PhCH}=\text{CHCOOH})^+]$, base peak, and 131 $(\text{PhCH}=\text{CHCO})^+$ in the EIMS, suggested the presence of a hydroxy and a cinnamate group in **2**, which was confirmed by the IR absorption bands at 3518 (OH) and 1719 cm^{-1} ($\text{C}=\text{O}$ of an α,β -unsaturated ester). Another carbonyl band at 1763 cm^{-1} indicated that **2** is also a saturated γ -lactone. Similar to **1**, the ^1H NMR spectrum of **2** (Table 1) exhibited a set of signals corresponding to a cinnamate group at δ 6.55 (H-2'), 7.84 (H-3'), 7.31–7.46 (H-6', H-7', and H-8'), and 7.59 (H-5' and H-9'). The protons of another phenyl group (H-10 through H-14) were observed in the same range as H-6', H-7', and H-8'. Due to the proximity to the C-2 carbonyl in the γ -lactone ring, the downfield shifts of the H-3a and H-3b signals were observed at δ 2.72 (dd, $J = 19.0$ and 5.8 Hz) and 2.60 (d, $J = 19.0$ Hz), respectively. The COSY spectrum supported the assignments of the overlapping signals at δ 5.02–5.05 (2H) as H-4 and H-5, including the separated signals at δ 5.75 (d, $J = 2.6$ Hz), 4.27 (dd, $J = 8.6$ and 2.6 Hz), and 4.68 (d, $J = 8.6$ Hz) as H-6, H-7, and H-8, respectively. The COSY correlation between the H-8 signal and a broad singlet at δ 2.91 confirmed the location of the hydroxy group at position C-8. Eighteen carbon signals for 22 carbons were found present in the ^{13}C NMR spectrum of **2** (Table 1). The carbon types and assignments were analyzed by DEPT and 2D-NMR data. The presence of the cinnamate group at C-6 was established through the long-range HMBC correlations of H-6 to

Scheme 2. Preparation of (+)-Crassalactone B (**2**) and (+)-Crassalactone C (**3**) from (+)-Goniofufurone (**6**)^a

^a (a) Cinnamoyl chloride (1 equiv), Et₃N (2.5 equiv), and DMAP (4 equiv), rt, 4 h.

C-4, C-5, C-7, and C-1' (Table S1, Supporting Information). Compound **2** was further proved to possess the stereochemistry as (+)-goniofufurone (**6**) isolated from the same extract (for spectroscopic data of **6**, see the Supporting Information) and reported earlier from the stem bark of *Goniothalamus giganteus*.^{14a} By the reaction of (+)-**6** with cinnamic acid (1 equiv) under the conditions shown in Scheme 2, (+)-**2** and (+)-**3** were obtained in 13 and 12% yields, respectively. The physical and spectroscopic data of the natural (+)-**2** were identical (mp, optical rotation, IR, UV, MS, ¹H and ¹³C NMR) to the semisynthetic product. Hence, (+)-crassalactone (**2**) was suggested to possess the same relative configuration as its precursor (+)-goniofufurone (**6**). Since the absolute configuration of (+)-goniofufurone (**6**) has been determined previously through synthetic work,^{14b-d} the absolute configuration of (+)-crassalactone B (**2**) was established as 4*R*, 5*S*, 6*R*, 7*R*, and 8*R*.

(+)-Crassalactone C (**3**) was found to possess the molecular formula C₂₂H₂₀O₆ from the [M]⁺ peak at *m/z* 380 in the EIMS and confirmed by elemental analysis. The fragment ions at *m/z* 362 (M⁺ - H₂O), 148 (PhCH=CHCOOH)⁺, and 131 [(PhCH=CHCO)⁺, base peak], as well as the IR absorptions at 3460 (OH stretch) and 1716 cm⁻¹ (C=O stretch of cinnamate), indicated the presence of hydroxy and cinnamate groups in **3**. The absorption band at 1775 cm⁻¹ was assigned to the C=O stretch of a saturated γ -lactone moiety. By comparison of its ¹H NMR data (Table 1) with those of **2**, the structure of **3** was closely related to **2**. The locations of the hydroxyl group at C-6 and cinnamate group at C-8 in **3** were suggested by an upfield shift of the broad singlet at δ 4.42 (H-6) and a downfield shift of doublets at δ 6.00 (H-8, *J*_{7,8} = 9.2 Hz). Further confirmation was obtained through the observed HMBC correlations of OH-6 to C-5 and C-6, and H-8 to C-6, C-7, C-9, C-10, C-14, and C-1' (Table S1, Supporting Information). Other proton signals were found in accordance with those of **2**, whereas the ¹³C NMR signals (Table 1) showed 18 signals for 22 carbons, of which the carbon types were analyzed by DEPT experiments. The two downfield peaks at δ 175.3 and 167.5 were attributable to the carbonyls of saturated γ -lactone and cinnamate groups, respectively. As mentioned earlier, compound **3** was also obtained from the reaction of the isolated (+)-goniofufurone (**6**) with cinnamoyl chloride under the conditions shown in Scheme 2. The absolute configuration of (+)-crassalactone C (**3**) was thus proved to be 4*R*, 5*S*, 6*R*, 7*R*, and 8*R*.

Elemental analysis of (+)-crassalactone D (**4**) established its molecular formula as C₁₃H₁₂O₄. In its EIMS, the prominent peaks at *m/z* 214 [M⁺ - H₂O] suggested that **4** was a monohydroxy alcohol. The OH stretch band at 3469 cm⁻¹ in the IR spectrum confirmed the alcoholic character of **4**. The presence of an α,β -unsaturated γ -lactone unit in **4** was indicated by the two carbonyl absorbances at 1758 and 1750 cm⁻¹ and confirmed by the peak at δ 169.0 (C-2) in its ¹³C NMR spectrum (Table 1). The ¹H NMR spectrum of **4** (Table 1) showed signals for a phenyl group, consisting of two sets of multiplets at δ 7.37–7.41 (2H) and 7.29–7.34 (3H). The olefinic protons (H-3 and H-4) in the unsaturated γ -lactone ring resonated as a pair of doublets (*J* = 5.6 Hz each) at δ 6.28 and 7.29, respectively. The assignments of the other protons were made from its COSY spectrum. The signal of H-7 at δ 4.42 (ddd, *J* = 6.4, 1.9, and 1.9 Hz) showed strong cross-peaks with




Figure 2. X-ray ORTEP diagram of crassalactone D (**4**).




Figure 3. Distribution of $\Delta\delta_{S-R}$ values of the (*S*)- and (*R*)-MTPA esters of (+)-crassalactone D (**4**).

the signal of H-6a at δ 2.57 (dd, *J* = 14.3 and 6.4 Hz) and the signal of H-8 at δ 5.39 (d, *J* = 1.9 Hz), but very weak cross-peaks with the signal of H-6b at δ 2.31 (dd, *J* = 14.3 and 1.9 Hz). The hydroxyl group in **4** was suggested to be located at C-7 because a rather broad signal was observed for H-7. The ¹³C NMR and DEPT spectroscopic data of **4** (Table 1) indicated 11 signals for 13 carbons, consisting of one carbonyl, two quaternary carbons, nine methines, and one methylene. The signal of a quaternary carbon in the low-field region (δ 114.3) was assigned to the spiroketal carbon (C-5), since HMBC correlations of this signal to the H-3, H-4, H-6a, H-6b, H-7, and H-8 signals were observed (Table S1, Supporting Information). The complete structure and relative configuration of **4** were established by X-ray diffraction analysis. A view of the structure is provided in Figure 2.

The absolute stereochemistry of **4** was determined by the Mosher ester method.¹⁸ Crassalactone D (**4**) was reacted with (*S*)-(+)- and (*R*)-(–)- α -methoxy- α -(trifluoromethyl)phenylacetyl chloride at room temperature to give (*R*)- and (*S*)-MTPA esters [(*R*)- and (*S*)- α -methoxy- α -(trifluoromethyl)phenylacetic acid esters] of **4** in 21 and 19% yields, respectively. The observed chemical shift differences ($\Delta\delta_{S-R}$), shown in Figure 3, unambiguously established the absolute configuration at C-7 as *S*. Thus, the configuration in **4** was assigned as 5*S*, 7*S*, and 8*R*.

Pure isolated compounds (+)-**1**–(+)-**4**, the alkaloid aristolactam AII (**10**), and the (+)-triccinnamate **11** were evaluated for cytotoxic effects against a panel of cultured mammalian cell lines. The results are shown in Table 2. (+)-Crassalactone A (**1**) and (+)-crassalactone D (**4**) showed broad cytotoxic activity for all cell lines tested, while (+)-crassalactone B (**2**), **10**, and **11** exhibited moderate cytotoxic effects only for the P-388 cell line.

Table 2. Cytotoxicity of Compounds **1–4**, **10**, and **11** against Human and Rat Cancer Cell Lines

compound	cell line (ED ₅₀ μg/mL) ^a					
	P-388	KB	Col-2	BCA-1	Lu-1	ASK
1	0.18	1.7	1.9	0.92	1.9	1.6
2	3.8	>5	>5	>5	>5	>5
3	>5	>5	>5	>5	>5	>5
4	1.1	3.3	4.0	3.2	>5	3.1
10	2.7	>5	>5	>5	>5	>5
11	3.1	>5	>5	>5	>5	>5
ellipticine	0.52	0.65	0.53	0.65	0.56	0.60

^a Cytotoxic assay: ED₅₀ ≤ 5 μg/mL is considered active; P-388: murine lymphocytic leukemia, KB: human nasopharyngeal carcinoma, Col-2: human colon cancer, BCA-1: human breast cancer, Lu-1: human lung cancer, ASK: rat glioma.

Although the presence of styryl-lactones in the genus *Polyalthia* is unusual, altholactone has been reported previously from an unnamed species of this genus.¹⁵ Our work represents the second report on the discovery of styryl-lactones from the genus *Polyalthia*.

Experimental Section

General Experimental Procedures. Melting points (uncorrected) were recorded on a digital Electrothermal melting apparatus. Optical rotations were determined on a JASCO DIP 370 digital polarimeter using a 50 mm microcell (1 mL). UV spectra were measured in ethanol on a JASCO 530 spectrometer, and IR spectra were recorded on a Perkin-Elmer 2000 FT-IR spectrophotometer. The ¹H and ¹³C NMR spectra were recorded on a Bruker AV 500 spectrometer in CDCl₃, using TMS as internal standard. EIMS were recorded on a Thermo Finnigan Polaris Q mass spectrometer at 70 eV (probe). The HRMS were recorded on a Micromass model VQ-TOF spectrometer. Solvents for extraction, chromatography, and recrystallization were distilled prior to use. Silica gel 60 (Merck, 70–230 mesh) and silica gel plates (Merck, Kieselgel 60F₂₅₄, 0.5 mm) were used for column chromatography and preparative TLC, respectively.

Plant Material. The leaves and twigs of *P. crassa* Parker (Annonaceae) were collected from Kangkrachan District, Petchburi Province, in October 2001 and identified by one of us (T.S.). A voucher specimen (BKF no. 109931) of *P. crassa* has been deposited at the Forest Herbarium, Royal Forest Department, Bangkok, Thailand.

Extraction and Isolation. The air-dried and finely powdered mixed leaves and twigs of *P. crassa* (2.6 kg) were sequentially percolated with hexane (5 × 4 L), EtOAc (5 × 3.5 L), and MeOH (5 × 4 L), at room temperature. Removal of solvents yielded the hexane, EtOAc, and MeOH extracts in 91, 184, and 203 g quantities, respectively.

The cytotoxic EtOAc extract (183 g) was subjected to silica gel column chromatography (1.6 kg), eluting with EtOAc–hexane (0–100%), followed by MeOH–EtOAc (0–100%) to give fractions A1–A11 after combination and removal of solvents. Fraction A5 (4.92 g, eluted with 8–10% EtOAc–hexane) was further separated by column chromatography (silica gel, 20% acetone–hexane as eluent), followed by recrystallization with EtOAc–hexane to give cinnamic acid (185.5 mg). Fraction A7 (7.57 g, eluted with 20–30% EtOAc–hexane) was purified by column chromatography (silica gel, 4% EtOAc–CH₂Cl₂ as eluent) to yield fractions B1–B6. Fraction B4 (100.6 mg) afforded (+)-3-acetylaltholactone (**8**) (31.4 mg) after separation by preparative TLC (20% acetone–hexane as eluent), followed by recrystallization from EtOH–CH₂Cl₂. Fraction B5 (3.01 g) yielded (+)-altholactone (**7**) (2.53 g) as a pure yellow oil after column chromatography (60% EtOAc–hexane as eluent). Fraction A8 (8.09 g, eluted with 30–35% EtOAc–hexane) was further separated using a silica gel column (MeOH–EtOAc–CH₂Cl₂, 1:1:48, as eluent) to provide an additional amount of pure **7** (4.56 g). Fraction A9 (16.6 g, eluted with 40–50% EtOAc–hexane) was rechromatographed on a Sephadex LH-20 column (MeOH as eluent) to give fractions C1–C4. Further separation of fraction C4 (7.77 g) on a silica gel column (MeOH–CH₂Cl₂–hexane, 1:12:7, as eluent) yielded fractions D1–D5. Fraction D3 (882.5 mg) was further separated by column chromatography (2% acetone–CH₂Cl₂ as eluent) to give fractions E1–E7. Fraction E1 (50.2 mg) afforded aristolactam AII (**10**) (33.6 mg) upon recrystallization with MeOH–C₆H₆. Fraction E2 yielded (+)-crassalactone B (**2**) (22.7 mg) after

recrystallization with EtOH. Fraction E4 (882.5 mg), after preparative TLC (5% MeOH–CH₂Cl₂ as eluent) and recrystallization with EtOH, gave (+)-crassalactone C (**3**) (147.5 mg). Fraction E5 was further purified by column chromatography (40% EtOAc–hexane as eluent) to provide fractions F1–F4. Fraction F3 (252.9 mg) yielded (+)-crassalactone A (**1**) (67.7 mg) upon recrystallization with EtOAc–hexane. Fraction F4 gave (+)-goniopyrpyrone (**9**) (62.9 mg) after column chromatography (10% EtOAc–hexane as eluent) and recrystallization from EtOAc–hexane. Fraction E6 (2.38 g) afforded (+)-howiinol A (**5**) (390.9 mg) upon recrystallization with EtOH–CH₂Cl₂. An additional quantity of (+)-**5** (304.9 mg) was obtained after column chromatography (30% acetone–hexane as eluent) and recrystallization. Fraction D4 (941.6 mg) was further separated by passage on a silica gel column (10% EtOAc–CH₂Cl₂ as eluent) to yield fractions G1–G6. Fraction G1 yielded (+)-crassalactone D (**4**) (30.2 mg) after preparative TLC (5% EtOAc–CH₂Cl₂) and recrystallization with EtOAc–hexane. Fraction G3 (299.7 mg) provided (+)-goniofufurone (**6**) (87.8 mg) after column chromatography (50% EtOAc–hexane as eluent) and recrystallization with EtOAc–hexane. Fraction A10 (27.9 g, eluted with 50–80% EtOAc–hexane) was rechromatographed on a silica gel column (MeOH–CH₂Cl₂–hexane, 1:12:7, as eluent) to give fractions H1–H5. Fraction H3 (1.74 g) yielded an additional amount of (+)-**6** (128.3 mg) after separation on two consecutive silica gel columns (10% acetone–hexane and 2% MeOH–CH₂Cl₂ as eluents, respectively), followed by recrystallization with EtOAc–hexane.

(+)-Crassalactone A (**1**): white powder, mp 133–134 °C; [α]_D²⁸ +326.0 (c 0.1, CHCl₃); [α]_D³⁰ +329.6 (c 0.5, EtOH); UV (EtOH) λ_{max} (log ε) 224 (sh) (4.88), 277 (4.58) nm; IR (KBr) ν_{max} 3456, 1721, 1711, 1636, 1450, 1338, 1253, 1164, 1099, 1069, 985 cm⁻¹; ¹H and ¹³C NMR, Table 1; EIMS *m/z* 380 [M]⁺ (0.7), 362 [M⁺ – H₂O] (0.6), 344 [M⁺ – 2H₂O] (0.4), 273 (10), 178 (15), 148 (89), 131 (100); *anal.* C 69.44%, H 5.78%, calcd for C₂₂H₂₀O₆, C 69.47%, H 5.30%.

Preparation of (+)-Tricinamate **11 from (+)-Crassalactone A (**1**).** A mixture of (+)-crassalactone A (**1**) (38 mg, 0.1 mmol), cinnamic acid (32.6 mg, 0.22 mmol), DCC (47.4 mg, 0.23 mmol), and DMAP (48.9 mg, 0.40 mmol) in dry CH₂Cl₂ (6 mL) was stirred at room temperature for 3 h. The solution was quenched with water (10 mL) and extracted with CH₂Cl₂ (3 × 20 mL). The combined organic layers were washed successively with brine and water and dried over anhydrous MgSO₄. After solvent removal, the crude product (122.8 mg) was further purified by preparative TLC (silica gel, 40% EtOAc–hexane) to yield the (+)-tricinamate **11** (26.4 mg, 41% yield).

Preparation of (+)-Tricinamate **11 from (+)-Howiinol A (**5**).** A mixture of (+)-howiinol A (**5**) (38 mg, 0.1 mmol), cinnamic acid (32.6 mg, 0.22 mmol), DCC (47.4 mg, 0.23 mmol), and DMAP (48.9 mg, 0.40 mmol) in dry CH₂Cl₂ (6 mL) was stirred at room temperature overnight (14 h). The solution was quenched with water (10 mL) and extracted with CH₂Cl₂ (3 × 20 mL). The combined organic layers were washed successively with brine and water and dried over anhydrous MgSO₄. After solvent removal, the crude product (125.9 mg) was purified by preparative TLC (silica gel, 2% MeOH–CH₂Cl₂) to afford the (+)-tricinamate **11** (11.3 mg, 18% yield). Pure (+)-**11** was obtained as a white powder by recrystallization from EtOH–CH₂Cl₂, mp 195–197 °C; [α]_D²⁹ +175.8 (c 0.2, CHCl₃); UV (EtOH) λ_{max} (log ε) 221 (sh) (2.79), 274 (2.89) nm; IR (KBr) ν_{max} 1731, 1721, 1710, 1636, 1577, 1496, 1450, 1308, 1164, 1039, 979 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 7.76 (1H, d, *J* = 16.0 Hz, H-3''), 7.62 (1H, d, *J* = 16.0 Hz, H-3'), 7.57 (1H, d, *J* = 16.0 Hz, H-3''), 7.56–7.53 (2H, m, ArH), 7.49 (2H, dd, *J* = 7.9, 1.2 Hz, H-10, H-14), 7.43–7.30 (13H, m, Ar–H), 7.27–7.19 (3H, m, Ar–H), 7.05 (1H, dd, *J* = 9.7, 5.5 Hz, H-4), 6.49 (1H, d, *J* = 16.0 Hz, H-2''), 6.37 (1H, d, *J* = 16.0 Hz, H-2'), 6.28 (1H, d, *J* = 6.7 Hz, H-8), 6.27 (1H, d, *J* = 16.0 Hz, H-2'), 6.23 (1H, d, *J* = 9.7 Hz, H-3), 5.94 (1H, dd, *J* = 6.7, 4.1 Hz, H-7), 5.52 (1H, dd, *J* = 5.5, 3.1 Hz, H-5), 4.93 (1H, dd, *J* = 4.1, 3.1 Hz, H-6); ¹³C NMR (CDCl₃, 125 Hz) δ 165.5 (s, C-1'), 165.2 (s, C-1''), 165.1 (s, C-1'''), 161.8 (s, C-2), 146.7 (d, C-3'), 146.33 (d, C-3''), 146.27 (d, C-3'''), 140.5 (d, C-4), 135.7 (s, C-9), 134.1 (s, C-4'''), 134.0 (s, C-4''), 133.7 (s, C-4'), 130.64, 130.60, 130.57, 128.91, 128.85, 128.82, 128.78, 128.6, 128.3 (d each, ArCH), 127.3 (d each, C-10 and C-14), 124.6 (d, C-3), 117.1 (d, C-2''), 116.9 (d, C-2'), 116.1 (d, C-2'), 75.5 (d, C-6), 73.4 (d, C-8), 71.4 (d, C-7), 63.0 (d, C-5); EIMS *m/z* 640 [M]⁺ (0.06), 147 (7), 131 (100), 103 (31), 77 (9).

(+)-Crassalactone B (**2**): white powder, mp 171–173 °C; [α]_D²⁸ +8.0 (c 0.5, EtOH); UV (EtOH) λ_{max} (log ε) 224 (sh) (4.88), 279 (4.74) nm; IR (KBr) ν_{max} 3518, 1763, 1719, 1635, 1578, 1497, 1449, 1398,

1333, 1315, 1163, 1045, 901 cm^{-1} ; ^1H and ^{13}C NMR, Table 1; EIMS m/z 380 $[\text{M}]^+$ (0.6), 362 $[\text{M} - \text{H}_2\text{O}]^+$ (2), 232 (20), 173 (20), 160 (78), 148 (100), 131 (99), 126 (26); HRTOFMS (ESI positive) m/z 403.1158 (calcd for $\text{C}_{22}\text{H}_{20}\text{O}_6\text{Na}$, 403.1158).

(+)-Crassalactone **3** (**3**): white powder, mp 147–150 °C; $[\alpha]_D^{30}$ +98.4 (*c* 0.5, EtOH); UV (EtOH) λ_{max} (log ϵ) 223 (sh) (4.65), 277 (4.46) nm; IR (KBr) ν_{max} 3460, 1775, 1716, 1682, 1638, 1578, 1498, 1450, 1333, 1167, 1068, 1047, 1004, 981 cm^{-1} ; ^1H and ^{13}C NMR, Table 1; EIMS m/z 380 $[\text{M}]^+$ (1), 362 $[\text{M} - \text{H}_2\text{O}]^+$ (2), 335 (6), 275 (14), 232 (23), 173 (22), 148 (32), 131 (100); *anal.* C 69.19%, H 5.36%, calcd for $\text{C}_{22}\text{H}_{20}\text{O}_6$, C 69.47%, H 5.30%.

(+)-Crassalactone **4** (**4**): colorless needles, mp 138–139 °C; $[\alpha]_D^{30}$ +7.0 (*c* 0.2, EtOH); UV (EtOH) λ_{max} (log ϵ) 252 (2.89), 258 (2.90), 264 (2.80), 268 (sh) (2.64) nm; IR (KBr) ν_{max} 3469, 1758, 1750, 1608, 1500, 1455, 1413, 1347, 1312, 1191, 1129, 1097, 1056, 982, 925 cm^{-1} ; ^1H and ^{13}C NMR, Table 1; EIMS m/z 233 $[\text{M} + \text{H}]^+$ (1), 214 $[\text{M}^+ - \text{H}_2\text{O}]$ (3), 126 (22), 107 (100), 97 (27), 79 (42); *anal.* C 67.53%, H 5.70%, calcd for $\text{C}_{13}\text{H}_{12}\text{O}_4$, C 67.24%, H 5.21%.

Preparation of the (R)-MTPA Ester of (+)-4.¹⁸ (S)-(+)-MTPA Cl (25.3 mg, 0.100 mmol) was added to a CH_2Cl_2 (1 mL) solution of crassalactone **4** (11.9 mg, 0.051 mmol), DMAP (25.0 mg, 0.205 mmol), and Et_3N (0.32 mL, 0.24 M solution in CH_2Cl_2) at 0 °C. The reaction mixture was stirred at room temperature for 6 h. The solution was quenched with water (10 mL) and extracted with CH_2Cl_2 (3 \times 30 mL). The combined organic layers were washed successively with brine and water and dried over anhydrous MgSO_4 . After solvent removal, the crude product (18.6 mg) was purified by preparative TLC (silica gel, 5% MeOH– CH_2Cl_2) to give the (R)-MTPA ester of **4** (4.9 mg, 21% yield).

Preparation of the (S)-MTPA Ester of (+)-4.¹⁸ (R)-(–)-MTPA Cl (22.9 mg, 0.091 mmol) was added to a CH_2Cl_2 (1 mL) solution of crassalactone **4** (10.5 mg, 0.045 mmol), DMAP (22.1 mg, 0.181 mmol), and Et_3N (0.28 mL, 0.24 M solution in CH_2Cl_2) at 0 °C. The reaction mixture was stirred at room temperature for 4 h. The solution was quenched with water (10 mL) and extracted with CH_2Cl_2 (3 \times 30 mL). The combined organic layers were washed successively with brine and water and dried over anhydrous MgSO_4 . After solvent removal, the crude product (20.9 mg) was purified by preparative TLC (silica gel, 5% MeOH– CH_2Cl_2) to give the (S)-MTPA ester of **4** (4.4 mg, 19% yield).

X-ray Structure Determination of (+)-Crassalactone **4.** $\text{C}_{13}\text{H}_{12}\text{O}_4$, MW 232.24, monoclinic, $P2_1$, $a = 9.7649(9)$ Å, $b = 4.8852(3)$ Å, $c = 11.8369(11)$ Å, $\beta = 99.310(3)^\circ$, $V = 557.22(8)$ Å³, $D_x = 1.384$ g/cm³, $Z = 2$, $F(000) = 244$. A total of 6287 reflections, of which 1994 were unique reflections (1784 observed, $|F_o| > 4\sigma|F_o|$), were measured at room temperature from a $0.25 \times 0.15 \times 0.10$ mm³ colorless crystal using graphite-monochromated Mo $K\alpha$ radiation ($\lambda = 0.71073$ Å) on a Bruker-Nonius kappaCCD diffractometer. The crystal structure was solved by direct methods using SIR-97, and then all atoms except hydrogen atoms were refined anisotropically by full-matrix least-squares methods on F^2 using SHELXL-97 to give a final R -factor of 0.0375 ($R_w = 0.0986$ for all data).

X-ray Structure Determination of (+)-Howiinol **5.** $\text{C}_{22}\text{H}_{20}\text{O}_6$, MW 380.396, orthorhombic, $P2_12_12_1$, $a = 6.0723(4)$ Å, $b = 12.0285(6)$ Å, $c = 25.741(2)$ Å, $V = 1880.1(2)$ Å³, $D_x = 1.344$ g/cm³, $Z = 4$, $F(000) = 800$. A total of 6605 reflections, of which 2632 were unique reflections (1996 observed, $|F_o| > 4\sigma|F_o|$), were measured at room temperature from a $0.20 \times 0.05 \times 0.05$ colorless crystal using graphite-monochromated Mo $K\alpha$ radiation ($\lambda = 0.71073$ Å) on a Bruker-Nonius kappaCCD diffractometer. The crystal structure was solved by direct methods using SIR-97, and then all atoms except hydrogen atoms were refined anisotropically by full-matrix least-squares methods on F^2 using SHELXL-97 to give a final R -factor of 0.0505 ($R_w = 0.1175$ for all data).

Crystallographic data for structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre and allocated the deposition numbers CCDC 612409 for compound **4** and CCDC 612408 for compound **5**. Copies of the data can be obtained, free of charge, on application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-(0) 1223-336033 or e-mail: deposit@ccds.cam.ac.uk).

Cytotoxicity Testing. Cytotoxicity assays of compounds **1–4**, **10**, and **11** were performed employing the colorimetric method as described by Skehan et al.,¹⁹ and ellipticine was used as a positive control.

Acknowledgment. We thank the Thailand Research Fund for financial support (DBG4880014) to P.T., a Ph.D. scholarship to B.M. through the Royal Golden Jubilee Ph.D. Program, and an award of Senior Research Scholar to V.R. Thanks are also due to the Higher Education Development Project, Postgraduate Education and Research Program in Chemistry (PERCH), for support.

Supporting Information Available: HMBC correlations observed for (+)-crassalactones A–D (**1–4**) and physical and spectroscopic properties of (+)-howiinol **5** and (+)-goniofufurone (**6**). This material is available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- (a) Pharmaceutical Science, Mahidol University. *Siam Phi-Chacha-Ya-Prug*; Amarin Printing and Publishing: Bangkok, 1996; p 191. (b) Kanokmedhakul, S.; Kanokmedhakul, K.; Ohtani, I. I.; Isobe, M. *Phytochemistry* **1998**, *47*, 131–133.
- Connolly, J. D.; Haque, E.; Kadir, A. A. *Phytochemistry* **1996**, *43*, 295–297.
- (a) Wu, Y. C.; Duh, C. Y.; Wang, S. K.; Chen, K. S.; Yang, T. H. *J. Nat. Prod.* **1990**, *53*, 1327–1331. (b) Zhao, G.; Jung, J. H.; Smith, D. L.; Wood, K. V.; McLaughlin, J. L. *Planta Med.* **1991**, *57*, 380–383. (c) Ma, X.; Lee, I. S.; Chai, H. B.; Zaw, K.; Farnsworth, N. R.; Soejarto, D. D.; Cordell, G. A.; Pezzuto, J. M.; Kinghorn, A. D. *Phytochemistry* **1994**, *37*, 1659–1662. (d) Chen, C. Y.; Chang, F. R.; Shih, Y. C.; Hsieh, T. J.; Chia, Y.-C.; Tseng, H. Y.; Chen, H. C.; Chen, S. J.; Hsu, M. C.; Wu, Y. C. *J. Nat. Prod.* **2000**, *63*, 1475–1478.
- (a) Faizi, S.; Khan, R. A.; Azher, S.; Khan, S. A.; Tauseef, S.; Ahmad, A. *Planta Med.* **2003**, *69*, 350–355. (b) Murthy M. M.; Subramanyam, M.; Bindu, M. H.; Annapurna, J. *Fitoterapia* **2005**, *76*, 336–339.
- Kanokmedhakul, S.; Kanokmedhakul, K.; Yodbuddee, D.; Phonkerd, N. *J. Nat. Prod.* **2003**, *66*, 616–619.
- (a) Li, H. Y.; Sun, N. J.; Kashiwada, Y.; Sun, L.; Snider, J. V.; Cosentino, L. M.; Lee, K. H. *J. Nat. Prod.* **1993**, *56*, 1130–1133. (b) Tuchinda, P.; Pohmakotr, M.; Reutrakul, V.; Thanyachareon, W.; Sophasan, S.; Yoosook, C.; Santisuk, T.; Pezzuto, J. M. *Planta Med.* **2001**, *67*, 572–575.
- (a) Hara, N.; Asaki, H.; Fujimoto, Y. Gupta, Y. K.; Singh, A. K.; Sahai, M. *Phytochemistry* **1995**, *38*, 189–194. (b) Hao, X.-J.; Yang, X.-S.; Zhang, Z.; Shang, L. J. *Phytochemistry* **1995**, *39*, 447–448.
- (a) Goyal, M. M.; Gupta, A. *Indian Drugs* **1985**, *22*, 658. (b) Lue, Y. P.; Mu, Q.; Zheng, H. L.; Li, C. M. *Phytochemistry* **1998**, *49*, 2053–2056.
- (a) Gonzalez, M. C.; Serrano, A.; Zafra-Polo, M. C.; Cortes, D. *J. Nat. Prod.* **1995**, *58*, 1278–1284. (b) Zafra-Polo, M. C.; Gonzalez, M. C.; Tormo, J. R.; Estornell, E.; Cortes, D. *J. Nat. Prod.* **1996**, *59*, 913–916. (c) Gonzalez, M. C.; Sentandreu, M. A.; Rao, K. S.; Zafra-Polo, M. C.; Cortes, D. *Phytochemistry* **1996**, *43*, 1361–1364. (d) Zhu, W. M.; Hong, X.; Shen, Y. M.; Zhao, B. T.; He, H. P.; Hao, X. *Chin. Chem. Lett.* **2001**, *12*, 617–618. (e) Zhu, W. M.; Li, S. L.; Shen, Y. M.; Ning, X. J.; Zhao, B. T.; Hao, X. *J. Heterocycles* **2002**, *57*, 529–534.
- Kanokmedhakul, S.; Kanokmedhakul, K.; Kantikeaw, I.; Phonkerd, N. *J. Nat. Prod.* **2006**, *69*, 68–72.
- (a) Kunesch, N.; Cavé, A.; Leboeuf, M.; Hocquemiller, R.; Dubois, G.; Guittet, E.; Lallemand, J. Y. *Tetrahedron Lett.* **1985**, *26*, 4937–4940. (b) Lee, K. H.; Chuah, C. H.; Goh, S. H. *Tetrahedron Lett.* **1997**, *38*, 1253–1256. (c) Gonzalez, M. C.; Zafra-Polo, M. C.; Blazquez, M. A.; Serrano, A.; Cortes, D. *J. Nat. Prod.* **1997**, *60*, 108–110.
- (a) Tuchinda, P.; Pohmakotr, M.; Munyoo, B.; Reutrakul, V.; Santisuk, T. *Phytochemistry* **2000**, *53*, 1079–1082. (b) Thinapong, P.; Rangsiman, O.; Tuchinda, P.; Munyoo, B.; Pohmakotr, M.; Reutrakul, V. *Acta Crystallogr. Sect. C: Cryst. Struct. Commun.* **2000**, *C56*, e309–e310.
- (a) Sun, S. Y.; Yu, D. Q. *Chin. Chem. Lett.* **1997**, *8*, 293–294. (b) Chen, R. Y.; Yu, D. Q.; Ma, L.; Wu, F.; Song, W. *Z. Acta Pharm. Sin.* **1998**, *33*, 453–456.
- (a) Fang, X. P.; Anderson, J. E.; Chang, C. J.; Fanwick, P. E.; McLaughlin, J. L. *J. Chem. Soc., Perkin Trans. 1* **1990**, 1655–1661. (b) Shing, T. K. M.; Tsui, H. C.; Zhou, Z. H. *J. Chem. Soc., Chem. Commun.* **1992**, 810–811. (c) Shing, T. K. M.; Tsui, H. C.; Zhou,

- Z. H. *J. Org. Chem.* **1995**, *60*, 3121–3130. (d) Tsubuki, M.; Kanai, K.; Nagase, H.; Honda, T. *Tetrahedron* **1999**, *55*, 2493–2514.
- (15) Loder, J. W.; Neam, R. H. *Heterocycles* **1977**, *7*, 113–118.
- (16) Peris, E.; Estornell, E.; Cabedo, N.; Cortes, D.; Bermejo, A. *Phytochemistry* **2000**, *54*, 311–315.
- (17) (a) Crohare, R.; Priestap, H. A.; Farina, M.; Cedola, M.; Ruveda, E. A. *Phytochemistry* **1974**, *13*, 1957–1962. (b) Desai, S. J.; Prabhu, B. R.; Mulchandani, N. B. *Phytochemistry* **1988**, *27*, 1511–1515.
- (18) (a) Ohtani, I.; Kusumi, T.; Ishitsuka, M. O.; Kakisawa, H. *Tetrahedron Lett.* **1989**, *30*, 3147–3150. (b) Ward, D. E.; Rhee, C. K. *Tetrahedron Lett.* **1991**, *32*, 7165–7166.
- (19) Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. *J. Natl. Cancer Inst.* **1990**, *82*, 1107–1112.

NP060323U